New drug combo aims to shrink stomach tumors before surgery
NCT ID NCT07464756
First seen Mar 23, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This study tests whether adding the drugs SHR-1701 and apatinib to standard chemotherapy before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 80 adults will be randomly assigned to receive either SHR-1701 plus chemo or SHR-1701 with apatinib plus chemo before their operation. The main goal is to see if the cancer completely disappears after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.